AVITA Medical Appoints New Chief Medical Officer
Ticker: AVHHL · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1762303
| Field | Detail |
|---|---|
| Company | Avita Medical, Inc. (AVHHL) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $453,000, $113,250, $40,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, management-change
TL;DR
AVITA Medical names Dr. Hall as CMO, replacing Dr. Holder.
AI Summary
AVITA Medical, Inc. announced on June 28, 2024, the appointment of Dr. Michael J. R. Hall as Chief Medical Officer, effective immediately. Dr. Hall previously served as the company's Chief Medical Officer on an interim basis. The company also reported on the departure of Dr. Stuart A. Holder from his role as Chief Medical Officer.
Why It Matters
The appointment of a permanent Chief Medical Officer is crucial for guiding the company's clinical strategy and product development, potentially impacting future growth and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and does not involve significant financial transactions or operational changes that would inherently increase risk.
Key Players & Entities
- AVITA Medical, Inc. (company) — Registrant
- Dr. Michael J. R. Hall (person) — Appointed Chief Medical Officer
- Dr. Stuart A. Holder (person) — Departed Chief Medical Officer
- June 28, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of AVITA Medical, Inc.?
Dr. Michael J. R. Hall has been appointed as the new Chief Medical Officer of AVITA Medical, Inc.
When was the appointment of Dr. Michael J. R. Hall effective?
The appointment of Dr. Michael J. R. Hall was effective immediately as of June 28, 2024.
Who previously held the position of Chief Medical Officer on an interim basis?
Dr. Michael J. R. Hall previously served as the company's Chief Medical Officer on an interim basis.
Who has departed from the role of Chief Medical Officer?
Dr. Stuart A. Holder has departed from the role of Chief Medical Officer.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is June 28, 2024.
Filing Stats: 1,006 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-07-01 16:36:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar
- $453,000 — will receive (i) a lump sum payment of $453,000, less applicable withholdings, represen
- $113,250 — rement date, (ii) a lump sum payment of $113,250, less applicable withholdings, represen
- $40,000 — s. Shiroma will receive compensation of $40,000 for one month ending on July 31, 2024 u
Filing Documents
- rcel-20240628.htm (8-K) — 49KB
- rcel-ex99_1.htm (EX-99.1) — 16KB
- img262816717_0.jpg (GRAPHIC) — 20KB
- 0000950170-24-079679.txt ( ) — 213KB
- rcel-20240628.xsd (EX-101.SCH) — 25KB
- rcel-20240628_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 1, 2024, the Company issued a press release announcing the retirement of Ms. Shiroma and appointment of Ms. Kelsey as Chief Legal and Compliance Officer and Corporate Secretary, a copy of which is furnished herewith as Exhibit 99.1. The information under Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release of AVITA Medical, Inc. dated July 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc. Date: July 1, 2024 By: /s/ David O'Toole David O'Toole Chief Financial Officer